You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Baxter
AstraZeneca
Boehringer Ingelheim
Dow

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,387,191


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,387,191 protect, and when does it expire?

Patent 9,387,191 protects AURYXIA and is included in one NDA.

This patent has thirty patent family members in twelve countries.

Summary for Patent: 9,387,191
Title:Ferric citrate dosage forms
Abstract: Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).
Inventor(s): Le; Henry Trong (Englewood Cliffs, NJ)
Assignee: Keryx Biopharmaceuticals, Inc. (New York, NY)
Application Number:13/255,326
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,387,191
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 9,387,191

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,387,191

PCT Information
PCT FiledJuly 21, 2010PCT Application Number:PCT/US2010/042788
PCT Publication Date:January 27, 2011PCT Publication Number: WO2011/011541

International Family Members for US Patent 9,387,191

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010276242   Start Trial
Brazil 112012001372   Start Trial
Canada 2768656   Start Trial
China 102573807   Start Trial
China 108938585   Start Trial
China 109223724   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Dow
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.